TongliBio announces to complete a clinical phase I trial with TL-010 in South Africa

7/29/2019. TongliBio announces to complete a clinical phase I trial with TL-010. This is a phase 1, single center, open-label, randomized, five-treatment, five-period crossover study to assess the relative bioavailability and pharmacokinetics of TL-010  in healthy males and females.